Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-04-26
2011-04-26
Spector, Lorraine (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S350000, C530S387300, C530S387900, C530S388750, C530S388850, C424S178100, C424S192100
Reexamination Certificate
active
07932055
ABSTRACT:
Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.
REFERENCES:
patent: 6018026 (2000-01-01), Sledziewski et al.
patent: 6238890 (2001-05-01), Boime
patent: 6262244 (2001-07-01), Houchins et al.
patent: 6833441 (2004-12-01), Wang et al.
patent: 2003/0078385 (2003-04-01), Arathoon et al.
patent: 2003/0195338 (2003-10-01), Chung et al.
patent: 2004/0072256 (2004-04-01), Mendelboim et al.
patent: 2004/0138417 (2004-07-01), Fitzpatrick et al.
patent: WO 92/06204 (1992-04-01), None
patent: WO 95/33057 (1995-12-01), None
patent: WO 9734631 (1997-09-01), None
patent: WO 98/50431 (1998-11-01), None
patent: WO 99/28747 (1999-06-01), None
patent: WO 9929732 (1999-06-01), None
patent: WO 99/37772 (1999-07-01), None
patent: WO 0158957 (2001-08-01), None
patent: WO 02/03237 (2002-01-01), None
patent: WO 02/08272 (2002-01-01), None
patent: WO 02/12345 (2002-02-01), None
patent: WO 02/22153 (2002-03-01), None
patent: WO 02/101006 (2002-12-01), None
patent: WO 03/012069 (2003-02-01), None
Gunturi et al., Immunologic Research 30(1):29-34.
Hayer, Silvia et al, Natural Immunity, 1998, vol. 16, No. 2-3, p. 78.
Brooks, Andrews G. et al, Journal of Immunology, 1999, vol. 162, No. 1, pp. 305-313.
Vales-Gomez, M. et al, Embo Journal, 1999, vol. 18, No. 15, pp. 4250-4260.
Boyington et al., “Structure of CD94 Reveals a Novel C-Type Lectin Fold: Implications for the NK Cell-Associated CD94/NKG2 Receptors,” Immunity, 1999, vol. 10, No. 1, pp. 75-82.
Chang et al., “Molecular Characterization of Human CD94: A Type II Membrane Glycoprotein Related to the C-Type Lectin Superfamily,” European Journal of Immunology, 1995, vol. 25, pp. 2433-2437.
Clements et al., “The Production, Purification and Crystallization of a Soluble Heterodimeric Form of a Highly Selected T-Cell Receptor in Its Unliganded and Liganded State,” Acta Crystallographica, 2002, vol. 58, pp. 2131-2134.
Ding et al., “Direct Binding of Purified HLA Class I Antigens by Soluble NKG2/CD94 C-Type Lectins From Natural Killer Cells,” Scandinavian Journal of Immunology, 1999, vol. 49, pp. 459-465.
Farag et al., “New Directions in Natural Killer Cell-Based Immunotherapy of Human Cancer,” Expert Opinion on Biological Therapy, 2003, vol. 3, pp. 237-250.
Hendsch et al., “Preferential Heterodimer Formation Via Undercompensated Electrostatic Interactions,” Journal of the American Chemical Society, 2001, vol. 123, pp. 1264-1265.
Kabat et al., “Role That Each NKG2A Immunoreceptor Tyrosine-Based Inhibitory Motif Plays in Mediating the Human CD94/NKG2A Inhibitory Signal” Journal of Immunology, 2002, vol. 169, pp. 1948-1958.
Kaiser et al., “Interactions Between NKG2X Immunoreceptors and HLA-E Ligands Display Overlapping Affinities and Thermodynamics1,” Journal of Immunology, 2005, vol. 174, pp. 2878-2884.
Kim et al., “Heterodimeric CD3EY Extracellular Domain Fragments: Production, Purification and Structural Analysis1,” Journal of Molecular Biology, 2000, vol. 302, pp. 899-916.
Kontermann et al., “Recombinant Bispecific Antibodies for Cancer Therapy,” Acta Pharmacologicasinica, 2005, vol. 26, pp. 1-9.
Laugel et al., “Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition,” Journal of Biological Chemistry, 2005, vol. 280, pp. 1882-1892.
Le Drean et al., “Inhibition of Antigen-Induced T Cell Response and Antibody-Induced NK Cell Cytotoxicity by NKG2A: Association of NKG2A With SHP-1 and SHP-2 Protein-Tyrosine Phosphatases,” European Journal of Immunology, 1998, vol. 28, pp. 264-276.
Malmberg et al., “IFN-Y Protects Short-Term Ovarian Carcinoma Cell Lines From CTL Lysis Via a CD94/NKG2A-Dependent Mechanism,” Journal of Clinical Investigation, 2002, vol. 110, pp. 1515-1523.
Marvin et al., “Recombinant Approaches to IGG-Like. Bispecific Antibodies,” Acta Pharmacologicasinica, 2005, vol. 26, No. 6, pp. 649-658.
McPhee et al., “Engineering Human Immunodeficiency Virus 1 Protease Heterodimers as Macromolecular Inhibitors of Viral Maturation,” Proceedings of the National Academy of Sciences of the USA, 1996, vol. 93, pp. 11477-11481.
Nohaile et al., “Altering Dimerization Specificity by Changes in Surface Electrostatics,” Proceedings of the National Academy of Sciences of the USA, 2001, vol. 98, No. 6, pp. 3109-3114.
Ridgway et al., “Knobs-Into-Holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization,” Protein Engineering, 1996, vol. 9, No. 7, pp. 617-621.
Sal-Man et al., “Arginine Mutations Within a Transmembrane Domain of TAR, anEscherichia coliAspartate Receptor, Can Drive Homodimer Dissociation and Heterodimer Association In Vivo,” Biochemical Journal, 2005, vol. 385, pp. 29-36.
Sanni et al., “Exclusion of Lipid Rafts and Decreased Mobility of CD94/NKG2A Receptors at The Inhibitory NK Cell Synapse,” Molecular Biology of the Cell, 2004, vol. 15, No. 7, pp. 3210-3223.
Speiser et al., “In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma Specific Cytolytic T Lymphocytes,” Journal of Experimental Medicine, 1999, vol. 190, No. 6, pp. 775-782.
Wu et al., “Solution Assembly of the Pseudo-High Affinity and Intermediate Affinity Interleukin-2 Receptor Complexes,” Protein Science, 1999, vol. 8, pp. 482-489.
Zhu et al., “Remodeling Domain Interfaces to Enhance Heterodimer Formation,” Protein Science, 1997, vol. 6, pp. 781-788.
Friedrichsen Birgitte Nissen
Nørby Inga Sig Nielsen
Padkær Søren Berg
Spee Petrus Johannes Louis
Chen Teresa
Novo Nordisk A S
Spector Lorraine
LandOfFree
Soluble heterodimeric CD94/NKG2 receptors fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble heterodimeric CD94/NKG2 receptors fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble heterodimeric CD94/NKG2 receptors fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687074